ROCHESTER, Minnesota — Microsoft and Mayo Clinic announced Thursday the formal structure of a clinical pilot program that will embed Microsoft's newly launched Scout AI assistant into Mayo Clinic's patient triage and intake workflows, marking the most concrete step yet in a partnership that was broadly signalled earlier this week. The pilot, set to begin across three Mayo Clinic facilities in Rochester, Phoenix, and Jacksonville, will test whether Scout can safely surface relevant medical history, flag potential drug interactions, and guide patients toward appropriate care pathways before they see a physician.

The announcement follows Microsoft's Tuesday launch of Scout for Microsoft 365 and the company's high-profile disclosure that it was teaming with Mayo Clinic to address the surge in patients using AI chatbots for health questions. Thursday's development moves that relationship from a general statement of intent to an operationally defined trial with specific endpoints, patient volume targets, and safety guardrails developed in collaboration with Mayo's clinical informatics team.

Mayo Clinic's Chief Digital Officer, speaking at a joint press briefing in Rochester, emphasized that the pilot would operate under strict human-in-the-loop protocols, meaning no Scout-generated recommendation would reach a patient without physician review. Microsoft's health and life sciences division noted that Scout would draw exclusively on Mayo Clinic's curated clinical knowledge base rather than the open internet, a design choice intended to reduce the risk of hallucinated medical guidance that has drawn regulatory scrutiny elsewhere.

The partnership arrives as the U.S. Food and Drug Administration is actively developing its framework for AI-assisted clinical decision support tools, making the Mayo-Microsoft trial one of the most closely watched industry experiments in the space. Analysts at Gartner and KLAS Research said Thursday that the structured pilot model — with defined safety metrics and a planned six-month independent review — could serve as a template for other health systems considering similar deployments of large-language-model assistants in clinical settings.

Microsoft shares edged higher in early Thursday trading on the news, while healthcare technology stocks broadly gained as investors interpreted the announcement as validation that enterprise AI adoption in regulated industries is accelerating. The companies said full results from the pilot would be submitted to a peer-reviewed journal following the review period, with the goal of informing both internal scale-up decisions and potential FDA guidance on the category.